Pioglitazone Ameliorates Lipopolysaccharide-Induced Behavioral Impairment, Brain Inflammation, White Matter Injury and Mitochondrial Dysfunction in Neonatal Rats
Overview
Chemistry
Molecular Biology
Authors
Affiliations
Previous studies have demonstrated that pioglitazone, a peroxisome proliferator-activated receptor gamma (PPARγ) agonist, inhibits ischemia-induced brain injury. The present study was conducted to examine whether pioglitazone can reduce impairment of behavioral deficits mediated by inflammatory-induced brain white matter injury in neonatal rats. Intraperitoneal (i.p.) injection of lipopolysaccharide (LPS, 2 mg/kg) was administered to Sprague-Dawley rat pups on postnatal day 5 (P5), and i.p. administration of pioglitazone (20 mg/kg) or vehicle was performed 5 min after LPS injection. Sensorimotor behavioral tests were performed 24 h after LPS exposure, and changes in biochemistry of the brain was examined after these tests. The results show that systemic LPS exposure resulted in impaired sensorimotor behavioral performance, reduction of oligodendrocytes and mitochondrial activity, and increases in lipid peroxidation and brain inflammation, as indicated by the increment of interleukin-1β (IL-1β) levels and number of activated microglia in the neonatal rat brain. Pioglitazone treatment significantly improved LPS-induced neurobehavioral and physiological disturbances including the loss of body weight, hypothermia, righting reflex, wire-hanging maneuver, negative geotaxis, and hind-limb suspension in neonatal rats. The neuroprotective effect of pioglitazone against the loss of oligodendrocytes and mitochondrial activity was associated with attenuation of LPS-induced increment of thiobarbituric acid reactive substances (TBARS) content, IL-1β levels and number of activated microglia in neonatal rats. Our results show that pioglitazone prevents neurobehavioral disturbances induced by systemic LPS exposure in neonatal rats, and its neuroprotective effects are associated with its impact on microglial activation, IL-1β induction, lipid peroxidation, oligodendrocyte production and mitochondrial activity.
Mitochondrial Dynamics in Brain Cells During Normal and Pathological Aging.
Sukhorukov V, Baranich T, Egorova A, Akateva A, Okulova K, Ryabova M Int J Mol Sci. 2024; 25(23).
PMID: 39684566 PMC: 11641149. DOI: 10.3390/ijms252312855.
Fernandes M, Pernin F, Antel J, Kennedy T J Neurochem. 2024; 169(1):e16219.
PMID: 39253904 PMC: 11657931. DOI: 10.1111/jnc.16219.
Fleiss B, Gressens P Adv Neurobiol. 2024; 37:591-606.
PMID: 39207715 DOI: 10.1007/978-3-031-55529-9_33.
Wang K, Ojeda N, Wang H, Chiang H, Tucci M, Lee J Neurochem Int. 2024; 176:105743.
PMID: 38641026 PMC: 11102812. DOI: 10.1016/j.neuint.2024.105743.
PPAR Gamma Receptor: A Novel Target to Improve Morbidity in Preterm Babies.
Victor S, Forbes B, Greenough A, Edwards A Pharmaceuticals (Basel). 2023; 16(11).
PMID: 38004396 PMC: 10675178. DOI: 10.3390/ph16111530.